Ipsen S.A. (OTCMKTS:IPSEY) Sees Large Increase in Short Interest

Ipsen S.A. (OTCMKTS:IPSEY) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,000 shares, an increase of 100.0% from the March 31st total of 500 shares. Based on an average trading volume of 4,200 shares, the short-interest ratio is currently 0.2 days.

Ipsen Stock Performance

IPSEY traded up $0.20 on Friday, reaching $30.36. 549 shares of the stock were exchanged, compared to its average volume of 2,160. The company’s 50-day moving average price is $29.01 and its 200 day moving average price is $29.07. Ipsen has a fifty-two week low of $26.97 and a fifty-two week high of $34.34.

About Ipsen

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.